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Abstract: Adipokines are the primary mediators of adipose tissue-induced and regulated systemic 
inflammatory diseases; however, recent findings revealed that serum levels of various adipokines 
correlate also with the onset and the severity of dermatological diseases. Importantly, further data 
confirmed that the skin serves not only as a target for adipokine signaling, but may serve as a source 
too. In this review, we aim to provide a complex overview on how adipokines may integrate into 
the (patho) physiological conditions of the skin by introducing the cell types, such as keratinocytes, 
fibroblasts, and sebocytes, which are known to produce adipokines as well as the signals that target 
them. Moreover, we discuss data from in vivo and in vitro murine and human studies as well as 
genetic data on how adipokines may contribute to various aspects of the homeostasis of the skin, 
e.g., melanogenesis, hair growth, or wound healing, just as to the pathogenesis of dermatological 
diseases such as psoriasis, atopic dermatitis, acne, rosacea, and melanoma. 
Keywords: adipokines; keratinocytes; fibroblasts; sebocytes; melanocytes; hair growth; psoriasis; 
atopic dermatitis; acne; melanoma 
 
1. Introduction 
White adipose tissue (WAT) is present throughout the human body with a pivotal role in lipid 
storage, thermoregulation, mechanical organ protection and regulation of energy homeostasis [1], 
but with remarkable anatomical, ontogenic, metabolic, cellular, molecular and physiological 
differences between its two forms, namely the visceral and the subcutaneous ones [2,3]. Importantly, 
WAT is also an active endocrine tissue due to the secretion of various hormones and bioactive 
molecules called adipokines [4], and has a central role in the regulation of immune responses locally 
and systemically; thus, it is considered as an immunometabolic system [5]. Alterations in the number 
of WAT cells and their dysregulated functions, therefore results in the pathogenesis of various 
diseases such as obesity, insulin resistance, type 2 diabetes, cardiovascular diseases [6,7] but may also 
be involved in “non-typical metabolic diseases” such as psoriasis [8,9]. 
Adipokines are small molecular weight biologically active proteins primarily produced by 
adipocytes, however many members are expressed and secreted also by non-adipocyte cells [10]. As 
opposed to protein families—which share a specific domain structure and homologous, conserved 
amino acid sequence—adipokines constitute a merely functional category of diverse proteins and 
peptides which are active in cell signaling. Interestingly, beyond the significant conformational and 
structural differences across the adipokines, different isoforms may exist even for individual 
adipokines (e.g., adiponectin or apelin) [11]. Furthermore, adipokines (such as adiponectin, the 
member of the serine protease inhibitor (SERPIN) gene family (SERPINE1) or apelin) may undergo 
further structural reorganization when involved in pathological process [11,12]. 
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Not surprisingly, their receptors have a diverse repertoire as well, accounting for the wide range 
of signaling pathways which may be activated by adipokines. While some of the adipokines transmit 
their signals through designated receptors, others act through receptors of various cytokines and 
hormones [12]—for example, leptin exerts its biological effect through the leptin receptor (Ob-R), 
which belongs to the type I cytokine receptor family [13]; the receptors for chemerin, monocyte 
chemoattractant protein-1 (MCP-1) and apelin are G protein-coupled receptors (GPRs) [14–16], while 
effects of resistin, visfatin and fetuin-A are mediated through the insulin receptor and a pattern 
recognition receptor (Toll-like receptor [TLR] 4) [17–19]. Adiponectin receptors are the members of 
the progestin and adipoQ receptor family, while the zinc-α2-glycoprotein (ZAG) is a β2 adrenergic 
receptor agonist [20,21]. SERPINE1 binds to the urokinase receptor, lipocalin 2 (LCN2) is able to act 
through its own specific 24p3 receptor and in the case of omentin-1, no specific receptor has been 
identified so far [22–24]. Moreover, multiple isoforms of a given receptor could be present as well on 
various cell types, as it is in the case of Ob-R, which has multiple splice variants—but only the long 
isoform (Ob-Rb) contains all the intracellular motifs that are necessary to activate the Janus kinase 
2/signal transducer and activator of the transcription factor 3 (JAK2/STAT3) pathway [25]. 
Currently, more than 600 adipokines have been described in the human body with various 
biological properties. The most widely used classification places their inflammatory properties in the 
center and distinguishes pro-and anti-inflammatory adipokines. Up-regulation of pro-inflammatory 
adipokines leads to the development of a chronic, low-grade inflammatory state and contributes to 
metabolic dysfunction. On the other hand, the adipose tissue secretes certain anti-inflammatory 
adipokines as well, which are under intensive investigation regarding their role in these processes 
[9,26]. Although adipokines are the key mediators of various adipose tissue-induced and -regulated 
inflammatory diseases, it has become evident that they may also be active regulators of cutaneous 
inflammatory processes, which promoted the identification of adipokine source and target cells in 
the skin [27–29]. Up to now, adipokine research has acquired an indisputable place in dermatology, 
with a growing body of information regarding the role of adipokines in skin (patho) physiology. In 
this review, with the limitation of not involving interleukins and the skin-associated immune cells, 
we summarize the adipokines produced by different human skin cell types, and demonstrate how 
these adipokines may contribute to the development of various skin diseases. 
2. Expression of Adipokines in Skin Cells 
2.1. Keratinocytes 
Continuously proliferating and differentiating keratinocytes are the dominant cell type of the 
epidermis. Keratinocytes are able to secrete and to respond to a wide range of bioactive molecules 
including adipokines, thereby regulating skin homeostasis (Figure 1). 
Leptin, encoded by the “obese” (Ob) gene [30], is one of the first discovered and most-studied 
adipokines in skin biology. Generally, leptin acts as a regulatory factor through the central nervous 
system, balancing food intake and energy expenditure [31]. In addition to the JAK2/STAT3 signaling, 
Ob-Rb is able to regulate members of the mitogen-activated protein kinase (MAPK) family (p38 
MAPK), as well as, the stress activated c-Jun N-terminal kinase (JNK) and phosphatidylinositol 3-
kinase/protein kinase B (PI3K/Akt) pathways [25,32,33]. The common endpoint of these signaling 
pathways is nuclear factor kappa-B (NF-κB), the major transcription regulator of inflammatory 
mediators. Therefore, it is generally accepted that in the human skin, leptin acts as a pro-
inflammatory adipokine [34]. In the human epidermis, prominent leptin immunoreactivity could be 
observed in the basal and suprabasal layers and its biologically active receptor (Ob-Rb) was also 
found to be expressed by keratinocytes [35]. The leptin/STAT3 pathway is linked to the 
differentiation, proliferation and migration of keratinocytes and it is a potent regulatory factor of 
innate and adaptive immunity. In human keratinocytes in vitro, leptin is able to stimulate the 
expression of the antimicrobial peptide human β-defensin-2 (hBD-2) as well as the production of pro-
inflammatory cytokines (interleukin [IL]-6, IL-8 and tumor necrosis factor-α [TNF-α]) via STAT1, 
STAT3, JAK2, p38 MAPK and NF-κB pathways. [36,37]. However, in transgenic mice overexpressing 
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leptin in keratinocytes, although high serum leptin levels could be detected, a normal histological 
morphology of the epidermis and the epidermal appendages were observed with unaltered 
expression of differentiation and proliferation markers [38]. Whether these findings are mice specific, 
or highlight the importance of investigating the role of leptin in combination with other factors, calls 
for further studies. 
 
Figure 1. Overview of adipokines expressed and secreted by different human skin cell types and their 
effects on these cells. 
Visfatin (also known as pre-B-cell colony-enhancing factor (PBEF), or nicotinamide 
phosphoribosyltransferase (NAMPT)) was originally identified in human peripheral blood 
lymphocytes and was found to enhance the maturation of B-cell precursors [39]. In human 
keratinocytes, the expression of visfatin could be induced by epidermal growth factor (EGF) 
treatment and was able to enhance the proliferation and migration of these cells via extracellular 
signal-regulated kinases (ERK) 1/2 and JNK1/2 pathways [40]. In vitro experiments showed that 
visfatin activated the NF-κB, STAT3 and CCAAT/enhancer-binding protein (C/EBP) pathways, 
increasing the basal and TNF-α-induced mRNA expression and secretion of chemokines (CXCL8, 
CXCL10) and antimicrobial peptides (cathelicidin, hBD2, hBD3) in normal human keratinocytes 
(NHKs) [41,42]. Although it is obvious that visfatin acts as a pro-inflammatory mediator under the 
conditions studied so far [43,44], further investigations are needed to understand its role in the 
immunobiology of keratinocytes. 
Recent in vitro evidence showed that LCN2 (also known as neutrophil gelatinase–associated 
lipocalin (NGAL)) is another potential immunomodulatory adipokine as it was able to induce 
immune tolerance through modulation of regulatory T cell expansion [45]. Although both normal 
hair follicles and in vitro cultured keratinocytes express LCN2, its strong induction in the epidermis 
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can only be observed in certain skin diseases suggesting an association with pathological conditions 
in human skin [46]. In line with this, IL-1β, IL-17 and TNF-α treatment stimulated the secretion of 
LCN2 in NHK and HaCaT keratinocytes, and by ERK1/2 and p38 MAPK pathways, LCN2 was found 
to induce neutrophil chemotaxis [47,48]. Interestingly, a characteristic high expression of LCN2 was 
detected in the apical layer of the epidermis in sebaceous gland (SG) rich human skin as opposed to 
SG poor areas suggesting that LCN2 (together with other cytokines and antimicrobial peptides) has 
a role in the maintenance of the specific immune milieu of SG rich skin [49]. 
SERPINE1 (or plasminogen activator inhibitor type-1 (PAI-1)) has a major role in the modulation 
of extracellular matrix degradation and tissue remodeling [50]. The mRNA and protein expression of 
SERPINE1 are undetectable in normal mouse epidermis. However, its strong expression could be 
observed after mechanical injury or topical treatment with a specific NF-κB activator [51,52]. 
Adipokines with chemotactic properties are also found in keratinocytes. Chemerin (also known 
as retinoic acid receptor responder 2 (RARRES2), or tazarotene-induced gene 2 protein (TIG2)), has 
been introduced as a chemokine as it is able to exert a chemotactic effect through the p38 MAPK 
pathway on dendritic cells (DCs) and natural killer cells (NK cells) and regulates macrophage-
mediated immune responses [53]. The mRNA and protein expression of chemerin and its receptors 
(chemerin chemokine-like receptor 1 (CMKLR1) and (GPR1)) show a characteristic distribution in 
human skin. While chemerin is expressed primarily in the epidermis, CMKLR1 and GPR1 expression 
tends to be higher in the dermal compartment [14]. The dermal response to chemerin is most probably 
a result of the release from its site of synthesis in the epidermis triggered by danger signals. In human 
skin cultures as well as in mouse skin in vivo, microbial stimuli increase chemerin synthesis 
indicating that the epidermis is a functional microbe-responsive site of chemerin production [14]. In 
the same experimental models, psoriasis-related cytokines, IL-17 and IL-22 significantly down-
regulated chemerin expression [14]. Based on in vitro experiments, chemerin facilitated the secretion 
of IL-1β, IL-8, TNF-α, as well as of reactive oxygen species (ROS), and consequently activated the NF-
κB signaling in NHK and HaCaT cells [54]. Overexpression of bioactive chemerin by basal 
keratinocytes in transgenic mice revealed that chemerin is able to significantly delay tumor 
development and progression in a DMBA/TPA model of skin carcinogenesis [55]. 
In addition to chemerin, MCP-1, also known as C-C motif ligand 2 (CCL2) also has chemotactic 
activity with a primary function to recruit immune cells (e.g., monocytes, memory T lymphocytes 
and NK cells) to the site of inflammation [56]. In human keratinocytes, via p38 MAPK and NF-κB 
pathways, chemical stimuli or inflammatory factors (e.g., TNF-α and interferon-γ (IFN-γ)) are able 
to induce the mRNA and protein expression/secretion of MCP-1 but its presence is not detectable 
under basal conditions [57–59]. In vitro experiments have shown that MCP-1 treatment increased p53 
and p21 protein expression in NHKs through p38 MAPK signaling, suggesting that it might be 
involved in keratinocyte senescence [60]. Further animal studies proved that subcutaneous injection 
or epidermis-specific expression of MCP-1 induced neither spontaneous cutaneous inflammation nor 
did it result in tissue damage, but stimulated the recruitment of DCs and Langerhans cells into the 
epidermis [61,62]. Thus, it can be speculated that MCP-1 alone is inefficient to induce a local 
inflammatory response. 
Resistin is a cysteine-rich protein that influences glucose homeostasis through the regulation of 
the suppressor of cytokine signaling 3 (SOCS-3) [63]. With low levels of expression, resistin can be 
detected in the cytoplasm of the outer root sheath and epidermal keratinocytes [64], however, little is 
known about its effect on these cells, as monocytes and macrophages appear to be its major source 
and target cells [65]. 
Retinol-binding protein (RBP) 4 mobilizes retinol (vitamin A) from the liver to target tissues 
where it is taken up through the transmembrane protein stimulated by retinoic acid 6 (STRA6) [66]. 
Although STRA6 is constitutively expressed in NHK and HaCaT keratinocytes and down-regulation 
of this receptor leads to hyperproliferation in vitro and in vivo skin models [67], the role of RBP4 in 
human keratinocytes is not fully known and clarified. 
Apelin is an endogenous ligand of the GPR called APJ [16]. Although the expression of apelin 
in the epidermis has not been studied, transgenic overexpression of apelin in mouse keratinocytes 
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resulted in enlarged blood vessels in the dermis which was mainly mediated by endothelial cell 
aggregation [68]. This is not surprising because APJ is structurally related to the angiotensin II 
receptor type 1, and one of its major functions is the regulation of angiogenesis [69]. 
Fetuin-A can be produced primarily by hepatocytes and adipocytes, but keratinocytes and 
fibroblasts were also proposed to secrete it [70,71]. Low levels of fetuin-A was detected in the 
epidermis and in primary human keratinocytes, mainly at the cell membrane and in the cytoplasm 
[71]. Although fetuin-A results in morphological changes in HaCaT and primary keratinocytes and 
significantly promotes the migration of these cells in an EGF receptor (EGFR)-independent manner, 
further studies are needed to clarify its role in the homeostasis of keratinocytes. 
ZAG is involved in the regulation of obesity-associated inflammatory responses in hepatocytes 
[72]. Normal keratinocytes express ZAG which plays an important role in the terminal differentiation 
of these cells and thus in the cohesion of the stratum corneum [73]. 
Besides pro-inflammatory adipokines, anti-inflammatory adipokines are also found in the 
epidermis, although in smaller amounts. Adiponectin (ACRP, AdipoQ) is predominantly involved 
in the regulation of insulin sensitivity and whole body energy metabolism through its cell surface 
receptors (ADIPOR1 and 2) and via the AMP-activated protein kinase (AMPK) pathway [74]. Based 
on experiments performed in mouse models, disruption of both receptors abrogated adiponectin 
binding and action, but the two receptors affected different pathways with opposing effects [75]. As 
an anti-inflammatory adipokine, adiponectin is able to inhibit TLR-mediated NF-κB signaling, 
thereby abrogating lipopolysaccharide (LPS) induced TNF production and stimulating the release of 
IL-10 and IL-1 receptor antagonists (IL-1Ra) from human monocytes/macrophages [76–78]. In the 
human epidermis, adiponectin receptors are expressed mainly in the basal cell layer [79]. In NHK 
and HaCaT keratinocytes adiponectin is capable of enhancing cell proliferation, differentiation and 
migration, of increasing lipid contents via Sirtuin 1, , and of inhibiting TNF-α and IL-6 secretion [80–
82]. Furthermore, adiponectin down-regulates ultraviolet B (UVB) induced mRNA expression of 
hBD2 through the suppression of p38 and JNK MAPK signaling [83] and also acts on NHK filaggrin 
synthesis indicating that it may also be involved in skin diseases associated with disrupted barrier 
functions [84]. 
Omentin is also present in the epidermis of normal human skin, and its decreased protein 
expression has been described under pathological conditions, suggesting that omentin has an anti-
inflammatory effect [85]. The evaluation of the role of omentin-1 with relevance to keratinocyte 
function requires further experiments. 
The serpin protease inhibitor vaspin (SERPINA12) is also considered to be an anti-inflammatory 
adipokine. Keratinocytes are the major vaspin-expressing cells in the human skin [86]. Higher vaspin 
levels could be measured in differentiated keratinocytes, suggesting that its expression is associated 
with the maturation of these cells [87]. In co-cultures with immune cells, vaspin was able to modulate 
the crosstalk between keratinocytes and immune cells and attenuated the production of cytokines 
and chemokines of the inflammatory cells [87]. 
2.2. Fibroblasts 
The most abundant cell types in the dermis are fibroblasts, which are the major source of 
extracellular matrix components (collagen, elastin, and fibronectin), thus playing a fundamental role 
in developing the proper structure and elasticity of the skin. Given the close ontogenic relationship 
between fibroblasts and adipocytes, it is not surprising that fibroblasts are also able to produce 
adipokines [88,89] (Figure 1). 
mRNA and protein expression of leptin and its full-length receptor can be observed in human 
skin in vivo and in cultured fibroblasts [35,90]. In addition, leptin production is also detectable under 
basal conditions and can be induced by various stimuli [90,91]. Based on in vitro experiments, leptin 
has no effect on cell proliferation; however, it up-regulates hyaluronic acid production, reduces UV-
induced TNF-α release and matrix metalloproteinase (MMP) expression [92]. 
Although adiponectin is not expressed at mRNA level in human dermal fibroblasts, its receptors 
are present in these cells and are up-regulated after UV irradiation and wounding suggesting that 
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fibroblasts are potential adiponectin-responsive cells in the dermis [80,93,94]. In extracellular matrix 
regulation, adiponectin may exert a potent anti-fibrotic effect via AMPK signaling, while its impaired 
production is accompanied by abnormal fibroblast activation [95]. Moreover, exogenous adiponectin 
administration down-regulated the MMP expression and prevented UV-induced dermal matrix 
degradation via suppression of EGFR signaling in human foreskin fibroblasts [94]. 
Regarding chemoattractant proteins, although relatively high chemerin receptor expression can 
be observed in the dermis, chemerin itself is hardly detectable under normal conditions [14]. Its 
transcription and protein expression is however increased in senescent human dermal fibroblasts, 
enhancing the chemotaxis of tumor cells via activation of MAPK signaling [96]. Dermal fibroblasts 
also produce and secrete MCP-1, which is positively regulated by growth factors in both an auto- and 
a paracrine manner [15]. 
mRNA and protein expressions of apelin are also detectable in normal human fibroblasts, which 
can be reduced by transforming growth factor β (TGFβ) 1 stimulation. Vice versa, TGFβ1-induced 
fibrosis-related gene expression was inhibited by apelin treatment suggesting that apelin might have 
a potential role in blocking TGFβ1/Smad signaling under pathological conditions in dermal fibroblast 
[97]. 
High levels of fetuin-A were found throughout the dermal layers, with fibroblasts stained 
positive for fetuin-A; however, further details are needed to conclude on any of its possible biological 
relevance [71]. 
Progranulin was not detected at basal conditions in fibroblasts but its mRNA levels increased 
after injury [98]. 
2.3. Sebocytes 
SGs together with the hair follicle (HF) form the pilosebaceous unit with a primary role to 
produce sebum to cover the hair and the skin [99]. However, studies confirmed that the role of 
sebocytes is not limited to the production of lipids, but may have inflammatory roles as well in which 
sebocytes may utilize adipokines [99–101] (Figure 1). 
Intense leptin and leptin receptor expression was observed in the SGs under normal as well as 
pathological conditions [101,102]. Moreover, sebocytes were capable of increasing the secretion of 
leptin when activated with TLR2 and 4 activators [101]. Importantly, in response to leptin, sebocytes 
exerted pro-inflammatory responses such as enhanced inflammatory enzyme (5-lipoxygenase (5-
LOX) and cyclooxygenase-2 (COX-2)) and cytokine production (IL-6 and IL-8) via the activation of 
the NF-κB and STAT3 pathways, in vitro [102]. Based on further in vitro and in vivo experiments, 
leptin is involved in a complex regulation of lipid production in mice sebocytes by inducing the 
diglyceride acyltransferase (DGAT)-regulated sebaceous lipogenesis, promoting the enlargement of 
the intracellular lipid bodies and increasing the ratios of the produced unsaturated/saturated fatty 
acids [102,103]. Activated mammalian target of rapamycin complex 1 (mTORC1) signaling, a master 
regulator of sebocyte differentiation, also enhances sebocyte-derived leptin production, while leptin 
further stimulates mTORC1 and sterol regulatory element binding protein 1 (SREBP1) expression, 
which may have an important role in the pathogenesis of SG-associated diseases [104]. 
Although immunohistochemical analysis revealed that in vivo SGs and in vitro SZ95 cells 
expressed resistin, visfatin, SERPINE1 and omentin-1, the role of these adipokines in the biology of 
SGs is not fully elucidated [64,85,101]. Resistin was predominantly localized in the basal cells of SGs—
suggesting that it may play a role in the regulation of sebocyte proliferation and differentiation [64] 
—but with further studies needed to determine its role in SG physiology. 
The high levels of visfatin and SERPINE1 in sebocytes, which were also further increased upon 
TLR stimulation, support that these adipokines could be involved in the pro-inflammatory potential 
of SGs and may contribute to a specific dermal milieu and to extracellular matrix remodeling under 
pathological conditions [101]. 
Adiponectin and its receptors are also expressed in SGs of normal human skin and primary 
sebocytes [79,101,105]. In addition to promoting proliferation, adiponectin efficiently activates the 
AMPK/Akt pathways, induces the expression of SREBP1 and significantly up-regulates the 
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production of lipids such as cholesterols, triglycerides, wax esters and squalene in primary sebocytes 
[105]. Although SZ95 sebocytes were found to express adiponectin at the mRNA level under normal 
conditions—which was down-regulated by a TLR1/2 activator—its secretion was not detectable in 
the supernatants, calling for further studies to reveal the possible biological role for sebocyte derived 
adiponectin [101]. Omentin-1 was also found to be present in normal SGs by immunohistochemical 
analysis; however, its role in the SG biology was not examined in detail [85]. 
3. Adipokines in Physiological Processes in the Skin 
3.1. Melanogenesis 
Melanogenesis is a complex process under the regulation of signals from the endocrine, immune 
as well as the nervous system, leading to the production of the pigment melanin in the melanosomes 
of melanocytes [106]. Interestingly, studies have shown that certain adipokines are also able to 
influence directly or indirectly the process of melanogenesis (Figure 1). 
In the hypothesis that obesity might be associated with the reduction of melanogenesis, leptin 
became a major candidate, by increasing the levels of melanocyte stimulating hormone (MSH) 
antagonists in the circulation, that may result in a lower activity of circulating MSH and melanocortin 
1 receptor (MC1R) [107]. 
Adiponectin receptors were found to be expressed also in immortalized human and mouse 
melanocytes. In response to adiponectin, melanocytes decreased the production of melanin and 
expressed melanogenesis-associated genes at a lower levels via the AMPK/CREB-regulated 
transcription co-activators (CRTCs) pathway, suggesting that adiponectin is an anti-melanogenic 
factor [108]. As a biological relevance, in hyperpigmentary disorders such as melasma, the mRNA 
levels of adiponectin and its receptors were also down-regulated in the basal layer of the lesional skin 
of melasma patients compared to the non-lesional skin [108,109]. However, the serum levels of 
adiponectin, just as of leptin, were not significantly different between melasma and control patients 
[108].  
ZAG was also found to act on both normal and malignant melanocytes by inhibiting the 
production of melanin through post-transcriptional effects on tyrosinase protein [110] and inhibiting 
the proliferation of melanocytes, which may even have therapeutic implications in diseases with 
hypopigmentation such as vitiligo [111,112]. 
3.2. Hair Growth 
Both unwanted loss (i.e., various alopecia forms) as well as undesired overgrowth (i.e., hirsutism 
and hypertrichosis) of the hair can substantially impair the quality of life of patients. Hair growth 
disorders are usually caused by a disturbance of the strictly regulated life cycle of the HFs, i.e., the 
hair cycle [113]. This life-long cycling consists of growth (“anagen”), regressive (“catagen”), and 
quasi-quiescent (“telogen”) phases [114]. Obviously, both the hair cycle and the hair growth are 
under tight and quite complex neuroendocrine control [115–117], and, of great importance, 
adipokines were also shown to contribute to this regulation. 
Indeed, by using immunohistochemistry, leptin expression was demonstrated in the hair matrix, 
in the inner root sheath, as well as in the dermal papilla (DP) fibroblasts of human HFs, while its 
receptor (long isoform) was only found to be expressed by DP fibroblasts [118]. Pro-inflammatory 
cytokines as well as the growth factors that are known to suppress hair growth significantly reduced 
the production of leptin, whereas those that support hair growth did not affect its production, 
highlighting the possibility that leptinergic signaling may be involved in the initiation and/or 
maintenance of the anagen phase of HFs [118]. In line with this concept, transition from the first 
telogen to the second postnatal anagen phase was found to be delayed in db/db (leptin receptor-
deficient) mice. Moreover, via JAK2, STAT3 and ERK1 signaling, the local injection of recombinant 
leptin promoted hair regrowth after shaving, by stimulating telogen-to-anagen transition [119]. 
Careful analysis of the hair cycle-dependent expression of leptin revealed that it was expressed in DP 
fibroblasts and follicular epithelial cells of catagen and telogen HFs. Intriguingly, in early anagen, 
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leptin expression could only be detected in DP fibroblasts, and no leptin expression was found in late 
anagen HFs of wild-type mice [119]. In line with these observations, leptin expression in human DP 
fibroblasts was stronger in the catagen than in early anagen phase, and chemically mimicked hypoxia 
also promoted leptin release of DP fibroblasts isolated from male scalp HFs [119]. Based on these 
findings, the authors speculated that the hypoxic stress that usually accompanies catagen and telogen 
might be one of the positive regulators of the leptin production of DP fibroblasts, and this hypoxia-
driven local leptin release may later play a role in initiating telogen-to-anagen transition. Intriguingly, 
however, although administration of leptin increased the number of nestin+ progenitor cells via the 
STAT3 pathway in the mesenchyme of organ-cultured human skin, it failed to do so in the HF 
epithelium [120], indicating that leptin might be a necessary—but not sufficient—player in the 
ignition of the telogen-to-anagen transition. Considering that leptin mRNA expression in the dermal 
white adipose tissue (DWAT) of mice was the lowest in the early anagen, increased in the late anagen, 
and peaked in the telogen phase [121], one might speculate that DWAT-derived leptin may be 
involved in driving telogen-to-anagen transition. 
Intriguingly, certain data point to the fascinating possibility that putative leptinergic 
communication between DWAT and HFs may even be bidirectional. Indeed, it has recently been 
shown that DWAT undergoes major morphological changes during the spontaneous and induced 
murine HF cycling. Specifically, the thickness of DWAT is the greatest in late anagen, and decreases 
in the catagen and telogen phases [122]. Considering that leptin is thought to suppress lipid 
accumulation of DWAT [123] and that, as mentioned above, follicular leptin production is high in the 
catagen, telogen, and early anagen, but low in the late anagen phase [119], one might speculate that 
HF-derived local leptin production may reduce lipid accumulation of dermal white adipocytes. 
Intriguingly, although the above findings introduce leptin as a potent pro-anagen agent, certain 
data argue that the in vivo regulation might be more complex. Indeed, higher plasma leptin 
concentration was found to be associated with a higher risk of androgenetic alopecia (AGA) in men, 
and plasma leptin level was significantly higher in subjects with advanced AGA compared to subjects 
with mild AGA [124], suggesting that disturbed leptinergic signaling may play a role in the 
pathogenesis of the said disease. Moreover, leptin was found to suppress the growth of organ-
cultured mouse vibrissa [121], signifying that the final effect of leptin on hair growth (i.e., promotion 
or suppression) may also depend on the anatomical location as well as on yet unknown other 
biological variables. 
Importantly, leptin is not the sole hair-relevant adipokine. Indeed, adiponectin receptors were 
shown to be expressed in human HFs [79]. Moreover, adiponectin treatment promoted hair shaft 
elongation in microdissected human HFs ex vivo [79]. Similarly, SERPINE1 was also found to be a 
hair growth promoting adipokine. Indeed, it was shown to be expressed in HFs of female BALB/c 
mice [52]. Importantly, SERPINE1–/– mice were found to exhibit delayed hair growth as compared 
to wild-type littermates [125], highlighting the possibility that SERPINE1 may indeed be a potent 
auto- and paracrine pro-anagen regulator. 
In contrast to adiponectin and SERPINE1, overexpression of progranulin in keratin 5 (K5)+ cells 
decreased hair growth as well as the diameter of the hair shaft in mice by activating the p38 MAPK 
pathway [126]. Although only scant data are available in the literature, the serum level of the pro-
inflammatory visfatin was not significantly different in alopecia areata (AA) patients and healthy 
individuals, according to a case control study [127]. In contrast, serum level of LCN2 was found to 
be elevated in hidradenitis suppurativa (HS) patients and LCN2 was also found to be up-regulated 
in lesional skin of HS patients [47,128]. Intriguingly, follicular LCN2 expression is restricted to the 
inner root sheath, and it is thought to be a marker for dysregulated keratinocyte differentiation in the 
interfollicular epidermis, because it was not present in healthy human epidermis, but it became 
prominent in parakeratotic lesions (e.g., in psoriasis) [46]. 
3.3. Wound Healing 
Based on experiments in leptin-deficient animal models, numerous studies have confirmed that 
as an autocrine/paracrine regulator, leptin has a role also in regulating wound healing. During the 
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normal healing process, leptin was found to be expressed at the wound site. Furthermore, 
immunohistochemical staining revealed that Ob-Rb was strongly expressed in the highly 
proliferative keratinocytes at the wound margin [129]. Moreover, by activation of the STAT3 
pathway, topically administered leptin promoted wound healing in mouse skin by accelerating 
keratinocyte function and enhancing angiogenesis around the wounded area [130,131], while 
injection of anti-leptin antibodies into skin wounds reduced fibroblast functions. These findings 
altogether suggested that leptin from the circulation as well as produced by keratinocytes and 
fibroblasts might be an important regulatory factor in wound healing [132]. This observation was 
further supported by fibroblasts cultured from db/db mice, which exhibited impaired cell migration, 
vascular endothelial growth factor (VEGF) production and a disrupted response to hypoxia [133]. 
According to in vitro and in vivo experiments, visfatin may also effectively improve wound 
healing by enhancing the proliferation and migration of keratinocytes and fibroblasts via ERK1/2 and 
JNK1/2 signaling as well as via the induction of VEGF expression through the MAPK pathway [40]. 
LCN2 expression was also found to be elevated at the wound edge both in animal and in human 
experiments, suggesting that together with transcription factor 3 (Tcf3) and transcription factor 7-like 
1 (Tcf7l1), LCN2 may regulate epidermal cell differentiation, migration and may accelerate wound 
healing via STAT3 signaling [134,135]. During the course of a scratch wound closure, an up-
regulation of SERPINE1 via mitogen-activated extracellular signal-regulated kinase (MEK)/ERK and 
p38 signaling could be detected suggesting that the activation of this protein is required for epithelial 
cell migration and the global cutaneous injury response program [136,137]. Although elevated MCP-
1 protein expression could be detected in normal wound repair, this protein is not derived from 
keratinocytes, but rather from infiltrating immune cells at the site of inflammation, with a role yet to 
be clarified [138]. 
Adiponectin in human and mouse fibroblasts plays an important role in hyaluronic acid 
metabolism and collagen synthesis, which may have beneficial effects also in wound healing [139]. 
Moreover, in adiponectin-deficient mice, keratinocyte proliferation and migration were impaired via 
the ERK signaling pathway during wound repair, underpinning that adiponectin is an important 
regulatory factor in this process [80]. 
Progranulin has also been identified as a wound-related growth factor in the human skin, 
because its mRNA expression was highly induced in dermal fibroblasts after injury and promoted 
the division and migration in an ERK- and PI3K-dependent manner [98]. 
4. Adipokines in Skin Diseases 
4.1. Psoriasis 
In psoriasis, the dermal inflammation induces the hyperproliferation of keratinocytes, which 
leads to the appearance of its hallmark plaques on predilection sites such as elbows, knees, lower 
back and scalp but can be present throughout the whole body. Importantly, a growing body of 
evidence supports the concept that psoriasis is not limited to the skin, but that it is rather a systemic 
inflammation, linked to metabolic diseases [140–142]. Several studies are available examining the 
relationship between psoriasis and the plasma or the tissue expression levels of different adipokines, 
with no clear conclusions which may be explained with methodological differences or incomparable 
study populations regarding the severity of psoriasis and/or comorbidities of the patients. 
While studies showed that the serum leptin levels were elevated in psoriatic patients with 
normal body mass index (BMI) and correlated with the psoriasis area and severity index (PASI) scores 
[143–145]—suggesting that the increased leptin concentrations in the serum might not only be 
derived from adipocytes but also from dermal cells—another study did not find a relationship 
between the circulating leptin concentrations and the PASI score [146]. Making the picture more 
complicated, another study showed that the levels of leptin were decreased in psoriasis [147]. 
Regarding histological studies, leptin and leptin receptor expression were significantly higher in the 
skin of severe psoriasis patients with normal BMI than in patients with mild-moderate psoriasis and 
controls [143]. However, in another study that found correlation between the BMI and leptin serum 
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levels but not with the disease severity in obese psoriatic patients, there were no differences in the 
expression levels of leptin in the skin between the examined groups. Moreover, the epidermal layer 
of lesional psoriatic skin exhibited lower leptin receptor expression than the normal or the 
uninvolved skin [148]. Interestingly, leptin mRNA expression in the subcutaneous adipose tissue 
positively correlated with circulating levels of leptin, as well as with the severity of psoriasis and the 
BMI in obese psoriatic patients, which highlights that the subcutaneous adipose tissue (and its 
adipokines) may play an important regulatory role in the pathogenesis psoriasis [149]. 
Elevated levels of resistin were consistently observed in the circulation of psoriasis patients and 
positively correlated with the PASI score [145,148,150]. The serum level of progranulin was also 
increased in patients with psoriasis and its expression was elevated in the affected skin [151]. 
SERPINE1 expression was found to be higher in the biopsies of psoriatic patients’ skin, however the 
limited data allows only speculation on its role [152]. Although increased levels of visfatin were also 
observed in the psoriatic patients, it correlated with the BMI, but not with the disease severity 
[153,154]. Furthermore, a gene expression study showed that the expression of visfatin was increased 
in peripheral blood monomorphonuclear cells of patients with psoriasis [154]. Chemerin expression 
may also be associated with the psoriasis progression, because its lowest levels were observed in 
chronic plaque psoriatic skin [155]. While the circulating RBP levels were in the normal range both in 
uninvolved and lesional psoriatic skin, studies with fetuin-A are more contradictory; indeed, one 
study found elevated serum fetuin-A levels in psoriasis whereas others did not [156–159]. 
Unfortunately, only limited number of studies are available on ZAG, with one showing that its 
immunoreactivity exhibited higher intensity in the epidermal cell layers of psoriatic patients which 
might be responsible for the process of desquamation [73]. 
Regarding anti-inflammatory adipokines, serum adiponectin and omentin levels were 
significantly lower in psoriatic patients compared to healthy controls, and studies found a negative 
correlation with disease severity [147,150,160–164]. Notably, both adipokines showed lower mRNA 
and protein expressions in the skin of patients with psoriasis [85,165]. Interestingly, topical or 
systemic anti-psoriatic treatment was shown to increase adiponectin and omentin levels in the 
psoriatic patient group [150,161,166] suggesting that both adipokines may play a protective role in 
the development of psoriasis. Altered vaspin expression might also contribute to the maintenance of 
psoriasis, because its epidermal expression was also down-regulated in human lesional psoriatic skin 
[86,87]; however, studies reported both an unaltered as well as significantly lower serum vaspin 
concentrations in psoriatic patients [86,167]. 
The number and size of SGs are known to decrease in psoriasis [168]. Importantly, SGs were 
found to express leptin, resistin, visfatin and SERPINE1 in lesional skin samples of patients with 
psoriasis. This raises the possibility that alterations in the number amount of SGs as well as in their 
adipokine-release pattern might contribute to the pathogenesis of psoriasis. [101]. 
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variations, which 
result from a substitution of a single nucleotide in a specific position of the genome. SNPs in pro- and 
anti-inflammatory adipokine genes encoding leptin, leptin receptor, adiponectin and omentin were 
addressed in psoriasis; however, (with the exception of one study of the rs7799039 polymorphism in 
the leptin gene), researchers found no correlation or increased risk of psoriasis vulgaris with these 
polymorphisms [85,164,169–171]. 
The putative role of adipokine signaling in the pathogenesis of psoriasis is overviewed in Figure 
2. 
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Figure 2. Adipokines might be involved in the pathogenesis of psoriasis vulgaris. Note the simplified 
characteristic histopathological findings in psoriasis skin: hyperproliferation of keratinocytes (1), 
elongation of the dermal papillae (2), dilated blood vessels (3) and immune cell infiltration in the 
dermis (4). Hematoxylin eosin staining; original magnification: 50×. 
4.2. Atopic Dermatitis (AD) 
AD is a common chronic inflammatory skin disease usually with an early onset. People with AD 
have a dry and itchy skin with inflammation [172]. 
Although there is a consensus that adipokines might have a potential role in the pathogenesis of 
AD, further prospective, controlled studies with larger cohorts of patients are needed to confirm 
whether the alterations in adipokine levels precedes or “only” accompanies the manifestation of AD. 
Regarding leptin, studies showed that its serum levels were significantly elevated in children 
and adult patients with IgE-associated AD compared to healthy controls [173,174], whereas others 
found that the circulating leptin levels were decreased or had no statistically significant association 
in patients with AD [175–177]. 
In the case of resistin and LCN2 similar controversial observations are available. While elevated 
serum levels of resistin were reported in children with AD compared to healthy controls [178], studies 
with opposing results are also available [174,179]. Serum LCN2 levels were also significantly higher 
in patients with AD [180]; however, other studies reported its decreased concentrations [174,181]. 
ZAG, which might have a role in modulating the skin barrier functions and immune responses 
through influencing the Notch signaling, exhibited a reduced expression in both the serum and the 
skin of AD patients [182]. 
A decreased blood level of adiponectin has been found in AD [174,175], whereas no significant 
differences were detected in its serum levels when correlated with the SCORAD severity index score. 
Interestingly, the mean adiponectin levels in extrinsic AD were lower than in intrinsic AD [183]. 
In genetic studies, significant associations have been detected between the rs2167270 
polymorphism of leptin gene (A19G) and the rs3745367 polymorphism of resistin gene (G > A) with 
the incidence and development of AD [184,185]. 
The putative role of adipokine signaling in the pathogenesis of AD is overviewed in Figure 3. 
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Figure 3. Adipokines might be involved in the pathogenesis of atopic dermatitis. Note the simplified 
characteristic histopathological findings in AD skin: slight epidermal hyperplasia with impaired 
barrier function (1) and immune cell infiltration in the dermis (2). Hematoxylin eosin staining; original 
magnification: 50×. 
4.3. Acne Vulgaris 
Acne vulgaris is one of the most common inflammatory skin diseases, involving the 
pilosebaceous unit in SG rich areas of the body such as the face, the chest and the back [99]. 
Considering that sebocytes, similarly to adipocytes, are highly active in lipid metabolism, we 
previously performed a comprehensive analysis and revealed that SGs express a characteristic set of 
adipokines also in acne skin samples, and their secretion may be modulated by acne related 
pathogenic (TLR) and therapeutic (isotretinoin) stimuli. [101]. 
Among the adipokines, the effects of leptin has been studied the most. Acting in an autocrine 
manner, leptin may be involved in an increased lipid metabolism and pro-inflammatory 
cytokine/enzyme production by activating the STAT3 pathway as observed in human SZ95 sebocytes 
in vitro, which resembled the changes detected in the sebum of acne patients [102,186]. While through 
augmenting Th17/IL-17 signaling and enhancing the secretion of pro-inflammatory cytokines by 
immune cells, leptin may also be involved in generating the pathological immune-milieu 
characteristic for lesional acne skin [187–190]. Ductal hypoxia, occurring in the obstructed follicles, 
has been also linked to the development of acne and hypoxia-inducible factor 1-α (HIF-1α) was 
shown to promote leptin expression [91,191]. Because mTORC1 is a potential regulator of HIF-1α, 
activation of the mTORC1 pathway therefore could also alter the sebocyte-derived leptin production 
[104]. Interestingly, the findings that leptin and other factors from the “Western diet” may activate 
the mTORC1 pathway, which, in turn, further enhances leptin production, suggest a possible role for 
the leptin-mTORC1 axis to link nutrition with the development of acne [104,192]. 
Although linking the dysregulated adipokine function with acne vulgaris is an intriguing area, 
the available data on the serum levels can only be evaluated to a limited extent. The results are 
inconsistent and difficult to interpret or to compare also in the context of acne because: 1) small 
groups of patients were studied; 2) there are mostly insufficient data regarding acne severity; and 3) 
significant heterogeneity can be observed among the studies. 
Although some papers demonstrated that there was no significant difference between 
circulating leptin, adiponectin, and RBP4 levels in patients with acne vulgaris, others found higher 
leptin and lower adiponectin serum concentrations [193–196]. Interestingly, isotretinoin (the most 
effective anti-acne agent) altered adiponectin levels and decreased leptin levels, which were 
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significantly lower in the acne patients compared with the control group already at the basal levels 
[196,197]. 
In the available genetic studies, the resistin gene rs1862513 (+299G > A) and rs3745367 (−420C > 
G) polymorphisms were strongly associated with familial acne vulgaris and the severity of symptoms 
but not with the acne types [198,199]. Moreover, the omentin gene rs2274907 (Val109/Val109) 
polymorphism leading to protein dysfunction, increases the predisposition to acne vulgaris [200]. 
The putative role of adipokine signaling in the pathogenesis of acne is overviewed in Figure 4. 
 
Figure 4. Adipokines might be involved in the pathogenesis of acne vulgaris. Note the simplified 
characteristic histopathological findings in acne: ductal hyperkeratosis (1), altered sebum production 
by sebocytes (2) and immune cell infiltration in the dermis (3). Hematoxylin eosin staining; original 
magnification: 50×. 
4.4. Rosacea 
Rosacea is a chronic inflammatory skin disease with clinical features such as dry skin, 
teleangiectasias and papulopustular lesions primarily on the face, but it may have ocular 
manifestations as well. In its development, genetic and environmental factors such as colonization of 
Demodex folliculorum (D. folliculorum) are suggested to play roles [201]. Although pro-
inflammatory cytokines and chemokines were addressed [202–204], little is known about how 
adipokines may be involved in the development and progression of rosacea. In an in vitro rosacea 
skin lesion model, in response to the antibacterial peptide LL-37 (cathelicidin) the production of 
MCP-1 was increased in HaCaT keratinocytes through the activation of JAK2/STAT3 signaling, 
suggesting that these pathways may play an important role in the inflammation caused by D. 
folliculorum [205]. Furthermore, in ex vivo skin models, as well as in NHK and HaCaT cells, anti-
parasitic and anti-inflammatory agents (e.g., ivermectin or artemisinin) reduced the LL-37-induced 
activation of NF-κB signaling and the secretion of MCP-1 [206,207]. However, in a prospective, 
observational study, there were no differences in serum and tear MCP-1 levels between the rosacea 
patients with or without ocular involvement and the control groups [208]. As SERPINs are known to 
interact with kallikreins, which are important regulators of the immune barrier alteration and skin 
desquamation, they might be involved in modifying the physiological structures of the epidermis, 
which can lead to the typical clinical signs in rosacea [209–211]. Epidermal LCN2 levels were also 
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significantly higher in papulopustular rosacea compared with controls and this expression level was 
strongly associated with the levels of permeability barrier structural components [212]. Leptin, 
adiponectin, resistin, SERPINE1 and visfatin were also detectable in the SGs of rosacea-involved skin, 
suggesting that through the secretion of these adipokines, SGs may contribute to the development of 
the characteristic inflammatory milieu in rosacea [101]. 
The putative role of adipokine signaling in the pathogenesis of rosacea is overviewed in Figure 
5. 
 
Figure 5. Adipokines may be involved in the pathogenesis of rosacea. Note the simplified 
characteristic histopathological findings in rosacea: impaired barrier function (1), interfollicular 
inflammation in the dermis (2). Hematoxylin eosin staining; original magnification: 50×. 
4.5. Malignant Melanoma 
Melanoma is the most aggressive skin tumor. Its risk factors include (among others) genetic 
background, sun exposure, and skin type [213]. 
Although, a growing body of evidence suggests that obesity is also a risk factor for human 
melanoma incidence, the available data are controversial. Some studies found a positive association 
between obesity and the risk of melanoma, while others have not [214–216]. Thus, elucidation of the 
putative role of adipokines both from systemic as well as from local origin requires further studies. 
Based on experiments performed by using genetically obese mice as well as mice suffering from 
diet-induced obesity, researchers found that adipokines might enhance the proliferation of 
melanoma cells and thus obesity could be considered as a tumor-promoting factor, whose presence 
may result in a poor prognosis of melanoma [217–219]. Indeed, melanoma progression was found to 
be partially decreased when the body weight was controlled by anti-obesity drugs or restriction of 
the calorie intake [219]. 
Leptin and its functional receptor was detected in human melanoma cell lines as well as in 
histological sections in melanomas. Moreover, the expression of Ob-Rb was increased in the WM793 
and WM35 melanoma cell lines compared to normal melanocytes [220,221]. In line with this data, 
serum leptin levels correlated positively with melanoma risk; however, a reverse correlation was 
found in the case of tumor thickness and serum levels of leptin receptor [222,223]. In human WM793 
and WM35 melanoma cell lines, leptin treatment activated the MAPK pathway and enhanced cell 
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proliferation, suggesting that leptin may act as a melanoma growth factor, and may contribute to the 
uncontrolled proliferation of these cells [220]. Leptin treatment following the subcutaneous injection 
of melanoma cells into C57BL/6 mice resulted in larger tumor size, higher capillary density and 
increased plasma levels of VEGF, supporting that, as an angiogenic and mitogenic factor, leptin could 
promote melanoma growth [224]. Resistin, apelin and visfatin are also able to act on melanoma cells 
by enhancing the proliferation, accelerating the tumor growth and triggering the redox adaptation 
responses through an insulin receptor independent pathway [217,225,226]. Moreover, human MeWo 
and HMCB melanoma cells are able to produce visfatin, which can activate the MAPK, the AKT and 
the NF-κB pathways [227]. Providing further relevance for visfatin in the progression of melanoma, 
its elevated levels were found in the serum of patients with BRAF-mutated metastatic melanoma with 
decreasing concentrations in response to BRAF/MEK inhibitor therapy [228]. The decreased 
expression of chemerin in murine and human melanomas was associated with a poor prognosis, 
suggesting an impaired anti-tumor NK cell recruitment in the background, which can be observed in 
the tumor microenvironment, aggravating the disease [229,230]. SERPINE1 may be involved in the 
regulation of the invasion of malignant cells and the formation of metastasis with its effect on tissue 
matrix remodeling; thus, it may be considered as a poor prognostic biomarker in human melanomas 
[231]. 
The protective role of adiponectin in melanoma pathogenesis also calls for further investigations, 
as a remarkable but statistically non-significant reverse correlation of serum adiponectin levels were 
found in melanoma patients in a case-control study [232]. 
The putative role of adipokine signaling in the pathogenesis of melanoma is overviewed in 
Figure 6. 
 
Figure 6. Adipokines might be involved in the pathogenesis of malignant melanoma. Note the 
simplified characteristic histopathological findings in melanoma: invasion of the malignant cells (1), 
increased vascularization (2) and immune cell infiltration (3). Hematoxylin eosin staining; original 
magnification: 50×. 
5. Conclusions 
In this review, we attempted to summarize and highlight the complexity of the adipokines and 
their related signaling pathways in the skin, which may lead to proven and in some cases presumed 
changes in the function of various skin cell types. While adipokines, both as targets and tools, are 
potential candidates for therapies not only in obesity and metabolic diseases, but also in 
lipodystrophy, infertility and bone growth [233], there is still limited data on their possible 
application to treat skin diseases. Moreover, we need not only to understand their complex actions 
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in the skin and with that the possible side effects, but their targeted delivery to the skin cells just as 
utilizing the mechanisms that could induce or inhibit their local expression/secretion should be 
revealed as well. In summary, it appears that our knowledge on the role of adipokines to regulate the 
(patho)physiological changes in the skin is still in an early phase, calling for further studies to reveal 
their biological relevance and to deliver adipokine-based therapeutic solutions. 
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5-LOX 5-lipoxygenase 
AA Alopecia areata 
ACRP/AdipoQ Adiponectin 
AD Atopic dermatitis 
ADIPOR Adiponectin receptor 
AGA Androgenetic alopecia 
Akt Protein kinase B 
AMPK AMP-activated protein kinase 
APJ Apelin receptor 
BMI Body mass index 
BRAF B-Raf proto-oncogene serine/threonine kinase 
C/EBP CCAAT/enhancer-binding protein 
CCL2 C-C motif ligand 2 
CMKLR1 Chemerin chemokine-like receptor 1 
COX-2 Cyclooxygenase-2 
CRTCs CREB-regulated transcription co-activators 
CXCL (C-X-C motif) ligand 
DC Dendritic cell 
DGAT Diglyceride acyltransferase 
DP Dermal papilla 
DMBPA/TPA Dimethylbenz[a]anthracene/12-O tetradecanoylphorbol-13-acetate 
DWAT Dermal white adipose tissue 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ERK Extracellular signal-regulated kinases 
GPR1 G protein-coupled receptor 1 
hBD-2 Human β-defensin-2 
HF Hair follicle 
HIF-1α Hypoxia-inducible factor 1-α 
HS Hidradenitis suppurativa 
IFN-γ Interferon-γ 
IL Interleukin 
JAK2 Janus kinase 2 
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JNK c-Jun N-terminal kinase 
LCN2 Lipocalin2 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
MC1R Melanocortin 1 receptor 
MCP-1 Monocyte chemoattractant protein-1 
MEK Mitogen-activated protein kinase kinase 
MMP Matrix metalloproteinase 
MSH Melanocyte stimulating hormone 
mTORC1 Mammalian target of rapamycin complex 1 
NAMPT Nicotinamide phosphoribosyltransferase 
NF-κB Nuclear factor kappa-β 
NGAL Neutrophil gelatinase–associated lipocalin 
NHK Normal human keratinocyte 
NK cell Natural killer cell 
Ob-Rb Leptin receptor 
PAI-1 Plasminogen activator inhibitor type-1 
PASI Psoriasis area and severity index 
PBEF Pre-B-cell colony-enhancing factor 
PI3K Phosphatidylinositol 3-kinas 
RARRES2 Retinoic acid receptor responder 2 
RBP Retinol-binding protein 
ROS Reactive oxygen species 
SCORAD SCORing Atopic Dermatitis 
SERPIN Serine protease inhibitor 
SG Sebaceous gland 
SNP Single nucleotide polymorphism 
SOCS-3 Suppressor of cytokine signaling 3 
SREBP1 Sterol regulatory element binding protein 1 
STAT3 Signal transducer and activator of transcription factor 3 
STRA6 Signaling receptor and transporter of retinol STRA6 
SZ95 Human sebaceous gland cell line 
Tcf Transcription factor 
TGFβ Transforming growth factor β 
Th T helper cell 
TIG2 Tazarotene-induced gene 2 protein 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor-α 
UVB Ultraviolet B 
VEGF Vascular endothelial growth factor;  
WAT White adipose tissue 
ZAG Zinc α2-Glycoprotein 
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